Insulin Regular (Lexi-Drugs)

Pronunciation

(IN soo lin REG yoo ler)

Brand Names: US

HumuLIN R U-500 (CONCENTRATED); HumuLIN R U-500 KwikPen; HumuLIN R [OTC]; NovoLIN R ReliOn [OTC]; NovoLIN R [OTC]

Brand Names: Canada

Entuzity Kwikpen

Pharmacologic Category

Insulin, Short-Acting

Dosing: Adult

Note: Regular insulin is a short-acting insulin. Insulin requirements vary dramatically between patients, and therapy requires dosage adjustments with careful medical supervision.

Diabetes mellitus, type 1: SubQ:

Note: Regular insulin must be used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or in a continuous subcutaneous infusion pump. The total daily doses (TDD) presented below are expressed as the total units/kg/day of all insulin formulations combined.

General insulin dosing (off-label):

Initial TDD: ~0.4 to 0.5 units/kg/day (AACE/ACE [Handelsman 2015]; ADA 2018); conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid the potential for hypoglycemia; higher initial doses may be required in patients who are obese, sedentary, or presenting with ketoacidosis (AACE/ACE [Handelsman 2015]; ADA 2018).

Usual TDD maintenance range: 0.4 to 1 units/kg/day in divided doses (ADA 2018)

Division of TDD (multiple daily injections):

Basal insulin: Generally, 40% to 50% of the TDD is given as basal insulin (intermediate [NPH]- or long-acting [eg, glargine, degludec, detemir]) in 1 to 2 daily injections (AACE/ACE [Handelsman 2015]; ADA 2018).

Prandial insulin: The remaining portion (ie, 50% to 60%) of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, lispro, aspart, glulisine, insulin for inhalation) or short-acting (regular) insulin (AACE/ACE [Handelsman 2015]; ADA 2018).

Dose adjustment: Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen that most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.

Diabetes mellitus, type 2: SubQ: Note: Rapid-acting analogs may be preferred over regular insulin for prandial insulin coverage due to their more rapid onset of action; however, regular insulin may be a practical option for some patients (ADA 2018; Lipska 2017).

Initial: 4 to 6 units or 0.1 unit/kg or 10% of the basal insulin dose (ADA 2018; Lipska 2017) administered before the largest meal of the day and usually given in addition to a regimen that includes basal insulin (ie, a long-acting insulin such as glargine, degludec, or detemir; or an intermediate-acting insulin such as NPH) and metformin +/- other noninsulin agents. Consider reducing the basal insulin dose if HbA1c is <8% when initiating prandial insulin (ADA 2018).

Dosage adjustment:

To reach self-monitoring glucose target: Adjust prandial insulin dose by 10% to 15% or 1 to 2 units; may adjust at weekly or twice weekly intervals (ADA 2018).

For hypoglycemia: If no clear reason for hypoglycemia, decrease prandial insulin dose by 2 to 4 units or by 10% to 20% (ADA 2018).

HbA1cstill not controlled despite titrations to reach glycemic targets: One option is to advance to ‘basal-bolus’ (ie, prandial insulin coverage before ≥2 meals per day) in addition to basal insulin and usually given in addition to metformin +/- other noninsulin agents (ADA 2018).

Conversion from U100 insulins (primarily basal-bolus analog regimen) to concentrated U-500 regular insulin (Bergen 2017; Hood 2015): Patients requiring >200 units of insulin/day:

Initial: Discontinue all other insulins; U-500 may be initiated conservatively with 80% of the TDD of the previous regimen (rounding down to the nearest 5 units); may administer in 2 divided doses (60% prior to morning meal; 40% prior to evening meal) or in 3 divided doses (40% prior to morning meal and 30% prior to lunch and evening meals). Alternatively, if hemoglobin A1c >8% or average blood glucose ≥183 mg/dL in the 7 days prior, may consider initiating U-500 with 100% of previous TDD administered in 2 or 3 divided doses.

Titration: Note: Base dosage adjustments on the median pre-meal glucose readings obtained over previous 3 days. With 3 times daily dosing, titrate at most 2 of the 3 doses, prioritizing for hypoglycemia; round to nearest 5 units.

Blood glucose <80 mg/dL: Reduce dose by 10%

Blood glucose 80 to 130 mg/dL: No change in dose

Blood glucose 131 to 180 mg/dL: Increase dose by 5%

Blood glucose 181 to 230 mg/dL: Increase dose by 10%

Blood glucose >230 mg/dL: Increase dose by 15%

Missed meal: Decrease U-500 dose by 50% for that meal

Patients with diabetes receiving enteral feedings (ADA 2018): SubQ: Note: TDD of insulin is divided into a basal component (intermediate- or long-acting insulin) and nutritional and correctional components (regular insulin or rapid-acting insulins).

Nutritional/Correctional: SubQ: 1 unit of regular insulin per 10 to 15 g of carbohydrate plus correctional regular insulin (as needed for hyperglycemia) administered every 6 hours or prior to each bolus feeding.

Patients with diabetes receiving parenteral feedings (ADA 2018):

IV (added to TPN solution): 1 unit of regular insulin per 10 g of carbohydrate added to TPN IV solution; adjust dose daily. One option is to increase the amount of regular insulin added to the TPN by two-thirds of the amount of the correctional insulin used on the previous day (ASPEN [Newton 2012]).

SubQ: Administer correctional regular insulin every 6 hours as needed for hyperglycemia.

Patients with diabetes undergoing surgery and using CSII pump (ADA 2018): On the morning of surgery or procedure, give 60% to 80% of the usual dose of pump “basal” insulin (rapid-or short-acting insulins) dose.

Cadaveric organ recovery (hormonal resuscitation) (off-label use): IV: Continuous infusion of 1 unit/hour (minimum dose) to maintain blood glucose of 120 to 180 mg/dL or 20 units as a bolus dose (after an IV bolus of dextrose 25 g) administered to the brain-dead donor who is hemodynamically unstable requiring significant vasopressor support; give concomitantly with levothyroxine or liothyronine (preferred), vasopressin, and methylprednisolone (Rosendale 2003a; Rosendale 2003b; Rosengard 2002; Salim 2007; Zaroff 2002).

Diabetic ketoacidosis (off-label use) (Kitabchi 2009): Only IV regular insulin should be used for severe diabetic ketoacidosis (pH <7, serum bicarbonate <10, and/or stupor/coma) or in patients with hypotension, anasarca, or critical illness. Treatment should continue until resolution of ketoacidosis (blood glucose <200 mg/dL and two of the following: Serum bicarbonate ≥15, venous pH >7.3, anion gap ≤12). Serum glucose is not a direct indicator of these abnormalities and may decrease more rapidly than correction of the ketoacidosis. Also, refer to institution-specific protocols where appropriate.

IV:

Bolus: 0.1 units/kg (optional)

Infusion: If a bolus was administered, follow with 0.1 units/kg/hour. If no bolus was administered, initiate with 0.14 units/kg/hour (lower doses may not achieve adequate insulin concentrations to suppress hepatic ketone body production).

Adjustment: If serum glucose does not fall by at least 10% in the first hour, give an IV bolus of 0.14 units/kg and continue previous regimen. In addition, if serum glucose does not fall by 50 to 75 mg/dL in the first hour, the insulin infusion dose should be increased hourly until a steady glucose decline is achieved Once serum glucose reaches 200 mg/dL, decrease infusion dose to 0.02 to 0.05 units/kg/hour or switch to SubQ rapid-acting insulin (eg, aspart, lispro) at 0.1 units/kg every 2 hours; administer dextrose-containing IV fluids to maintain serum glucose between 150 to 200 mg/dL until the resolution of ketoacidosis.

Transition from IV to SubQ insulin: After resolution of diabetic ketoacidosis, supplement IV insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1 to 2 hours between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels; for basal insulin analogues (eg, degludec, detemir, glargine), may consider an overlap of 3 to 4 hours due to their delayed onset of action (Fayfman 2017).

SubQ: Frequent administration of SubQ insulin regular has shown efficacy in diabetic ketoacidosis treatment; however, continuous IV insulin therapy is preferred (especially with severe ketoacidosis) due to a shorter half-life and ease of titration. SubQ administration may be considered in the non-ICU setting for mild to moderate ketoacidosis, but rapid-acting insulins (lispro and aspart) are preferred (Kitabchi 2009).

Hyperglycemia, critically ill (off-label use): Adults: IV continuous infusion: Insulin therapy should be implemented when blood glucose ≥150 mg/dL with a goal to maintain blood glucose <150 mg/dL (with values absolutely <180 mg/dL) using a protocol that achieves a low rate of hypoglycemia (ie, ≤70 mg/dL). Alternatively, other rapid acting insulin analogues (eg, insulin aspart or insulin glulisine) may also be used as a continuous infusion to maintain glycemic control (in place of regular insulin). Before discontinuation, stable ICU patients should be transitioned to a protocol-driven basal/bolus insulin regimen, based on insulin infusion history and carbohydrate intake, to avoid loss of glycemic control. Subcutaneous insulin therapy may be considered for selected clinically stable ICU patients (SCCM [Jacobi 2012]). Note: The Surviving Sepsis Campaign guidelines recommend initiating insulin dosing in patients with severe sepsis when 2 consecutive blood glucose concentrations are >180 mg/dL and to target an upper blood glucose ≤180 mg/dL (Rhodes 2017).

Hyperkalemia, moderate to severe (off-label use): IV: 10 units regular insulin mixed with 25 g dextrose (50 mL D50W) given over 15 to 30 minutes (AHA [Vanden Hoek 2010]) or alternatively, 10 units regular insulin as IV bolus followed by 50 mL D50W administered over 5 minutes (Allon 1990); a weight-based insulin dose of 0.1 units/kg (maximum: 10 units) may also be considered to reduce the risk of hypoglycemia (Brown 2018; Wheeler 2016). Effects on potassium are temporary; repeat dosing as needed (AHA [Vanden Hoek 2010]). As appropriate, consider methods of enhancing potassium removal/excretion.

Hyperosmolar hyperglycemic state (off-label use) (Kitabchi 2009): Only regular injectable insulin should be used. Infusion should continue until reversal of mental status changes and hyperosmolality. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Also, refer to institution-specific protocols where appropriate.

IV:

Bolus: 0.1 units/kg bolus (optional)

Infusion: If a bolus was administered, follow with 0.1 units/kg/hour. If no bolus was administered, initiate with 0.14 units/kg/hour.

Adjustment: If serum glucose does not fall by at least 10% in the first hour, give an IV bolus of 0.14 units/kg and continue previous regimen. In addition, if serum glucose does not fall by 50 to 75 mg/dL in the first hour, the insulin infusion dose should be increased hourly until a steady glucose decline is achieved. Once serum glucose reaches 300 mg/dL, decrease dose to 0.02 to 0.05 units/kg/hour; administer dextrose-containing IV fluids to maintain serum glucose between 200 to 300 mg/dL until the patient is mentally alert.

Transition from IV to SubQ insulin: After resolution of hyperosmolar hyperglycemic state, supplement IV insulin with SubQ insulin as needed until the patient is able to eat and transition fully to a SubQ insulin regimen. An overlap of ~1 to 2 hours between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels; for basal insulin analogues (eg, degludec, detemir, glargine), may consider an overlap of 3 to 4 hours due to their delayed onset of action (Fayfman 2017).

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer’s labeling; however, dosage adjustment may be needed as insulin requirements may be reduced due to changes in insulin clearance or metabolism. The following adjustments have been recommended (Aronoff 2007):

SubQ, IV:

CrCl >50 mL/minute: No dosage adjustment necessary.

CrCl 10 to 50 mL/minute: Administer 75% of normal dose and monitor glucose closely.

CrCl <10 mL/minute: Administer 50% of normal dose and monitor glucose closely.

Hemodialysis: Because of a large molecular weight (6,000 daltons), insulin is not significantly removed by hemodialysis; supplemental dose is not necessary

Peritoneal dialysis: Because of a large molecular weight (6,000 daltons), insulin is not significantly removed by peritoneal dialysis; supplemental dose is not necessary

Continuous renal replacement therapy: Administer 75% of normal dose and monitor glucose closely; supplemental dose is not necessary

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.

Dosing: Pediatric

The general objective of insulin replacement therapy is to approximate the physiologic pattern of insulin secretion. This requires a basal level of insulin throughout the day, supplemented by additional insulin at mealtimes. Since combinations using different types of insulins are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. The frequency of doses and monitoring must be individualized in consideration of the patient’s ability to manage therapy.

Type 1 diabetes mellitus: Infants (Limited data available), Children, and Adolescents: Note: Insulin regimens should be individualized to achieve glycemic goals without causing hypoglycemia. Multiple daily doses or continuous subcutaneous infusion guided by blood glucose monitoring are the standard of diabetes care. The daily doses presented are expressed as the total units/kg/day of all insulin formulations combined.

Initial dose: SubQ: 0.2 to 0.6 units/kg/day in divided doses. Conservative initial doses of 0.2 to 0.4 units/kg/day are often recommended to avoid the potential for hypoglycemia.

Division of daily insulin requirement (“conventional therapy”): Generally, 50% to 75% of the daily insulin dose is given as an intermediate- or long-acting form of insulin (in 1 to 2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.

Division of daily insulin requirement (“intensive therapy”): Basal insulin delivery with 1 or 2 doses of intermediate- or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.

Adjustment of dose: Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.

Usual maintenance range: 0.5 to 1 unit/kg/day in divided doses; doses must be individualized; however an estimate can be determined based on phase of diabetes and level of maturity (ISPAD [Danne 2014])

Partial remission phase (Honeymoon phase): <0.5 units/kg/day

Prepubertal children (not in partial remission): 0.7 to 1 units/kg/day

Pubescent Children and Adolescents: During puberty, requirements may substantially increase to >1.2 unit/kg/day and in some cases up to 2 units/kg/day

Continuous SubQ insulin infusion (insulin pump): A combination of a “basal” continuous insulin infusion rate with preprogrammed, premeal bolus doses which are patient controlled. When converting from multiple daily SubQ doses of maintenance insulin, it is advisable to reduce the basal rate to less than the equivalent of the total daily units of longer acting insulin (eg, NPH). Divide the total number of units by 24 to get the basal rate in units/hour. Do not include the total units of regular insulin or other rapid-acting insulin formulations in this calculation. The same premeal regular insulin dosage may be used.

Type 2 diabetes mellitus: Children ≥10 years and Adolescents: SubQ: The goal of therapy is to achieve an HbA1c <6.5% as quickly as possible using the safe titration of medications. Initial therapy in metabolically unstable patients (eg, plasma glucose ≥ 250 mg/dL, HbA1c >9% and symptoms excluding acidosis) may include once daily intermediate-acting insulin or basal insulin in combination with lifestyle changes and metformin. In patients who fail to achieve glycemic goals with metformin and basal insulin, may consider initiating prandial insulin (regular insulin or rapid acting insulin) and titrate to achieve goals. Once initial goal reached, insulin should be slowly tapered and the patient transitioned to lowest effective doses or metformin monotherapy if able (AAP [Copeland 2013]; ISPAD [Zeitler 2014]). Note: Patients who are ketotic or present with ketoacidosis require aggressive management as indicated.

Diabetic ketoacidosis (DKA): Limited data available: Infants, Children, and Adolescents: Note: Only IV regular insulin should be used for treatment of DKA; the rare exception where the use of SubQ rapid-acting insulin analogs (eg, aspart, lispro) may be appropriate is for patients with uncomplicated DKA in whom peripheral circulation is adequate and continuous IV regular insulin administration is not possible. Treatment should continue until resolution of acid-base abnormalities (eg, pH >7.3, serum HCO3 >15 mEq/L, and/or closure of anion gap); serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. As part of overall DKA management, dextrose should be added to IV fluids to prevent hypoglycemia, usually once serum glucose is between 250 to 300 mg/dL but it may be required sooner if serum glucose has decreased precipitously. Generally, only dextrose 5% is necessary and is added to NS or 1/2NS; however, dextrose 10% or 12.5% may be necessary in some cases (ADA [Wolfsdorf 2006]; ISPAD [Wolfsdorf 2014]). Refer to institution-specific protocols where appropriate.

Continuous IV infusion:

Initial: 0.05 to 0.1 units/kg/hour; continue the rate at 0.05 to 0.1 units/kg/hour if tolerated until resolution of ketoacidosis (pH >7.3; bicarbonate >15 mEq/L and/or closure of anion gap); Note: Some patients (eg, some young children with DKA, or older children with established diabetes) may have marked sensitivity to insulin requiring lower infusion rates; these lower infusion rates should only be used provided that resolution of the acidosis continues (ADA [Wolfsdorf 2006]; ISPAD [Wolfsdorf 2014]).

After resolution of DKA: Once ketoacidosis has resolved and oral intake is tolerated, transition to a SubQ insulin regimen. An overlap between discontinuation of IV insulin and administration of SubQ insulin is recommended to ensure adequate plasma insulin levels; timing of SubQ insulin administration prior to infusion discontinuation is dependent on type of insulin used; for SubQ regular insulin: 1 to 2 hours, or for rapid-acting insulin: 15 to 30 minutes (IPSAD [Wolfsdorf 2014]).

Hyperkalemia: Limited data available: Infants, Children, and Adolescents: IV: 0.1 unit/kg with 400 mg/kg of glucose; usual ratio of combination therapy of insulin to glucose is 1 unit of insulin for every 4 g of glucose (Hegenbarth 2008). An alternate approach is glucose 1 g/kg followed by 0.2 units of insulin/g of glucose administered over 15 to 30 minutes then infused continuously as a similar amount per hour (Fuhrman 2011). In adults, the usual dose is 10 units of insulin mixed with 25 g of dextrose (50 mL of D50W) administered over 15 to 30 minutes (ACLS [Vanden Hoek 2010]).

Hyperosmolar hyperglycemic state (HHS): Limited data available: Children and Adolescents: Note: Only regular IV insulin should be used. Insulin administration should be initiated when serum glucose concentration is no longer declining at a rate ≥50 mg/dL per hour with fluid administration alone; earlier initiation may be required in patients with severe ketosis and acidosis. Infusion should continue until reversal of mental status changes and hyperosmolality. Serum glucose is not a direct indicator of these abnormalities, and may decrease more rapidly than correction of the metabolic abnormalities. Refer to institution-specific protocols where appropriate.

Continuous IV infusion: Initial: 0.025 to 0.05 units/kg/hour; titrate dose to achieve a decrease in serum glucose concentration at a rate of 50 to 75 mg/dL per hour; higher rates of decline may be required in some patients; however, if rate of decline exceeds 100 mg/dL per hour discontinue infusion (ISPAD [Wolfsdorf 2014]; Zeitler 2011)

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in manufacturer’s labeling; insulin requirements are reduced due to changes in insulin clearance or metabolism;

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer’s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

Use: Labeled Indications

Diabetes mellitus, types 1 and 2: Treatment of type 1 diabetes mellitus and type 2 diabetes mellitus to improve glycemic control.

Note: Concentrated U-500 regular insulin is indicated only in patients requiring more than 200 units of insulin per day.

Use: Off-Label: Adult

  Cadaveric organ recovery (hormonal resuscitation)Level of Evidence [G]

Data from three retrospective cohort studies of brain-dead donors who successfully donated organs suggests that the use of intravenous regular insulin (and dextrose) given concomitantly with levothyroxine or liothyronine, methylprednisolone, and vasopressin may be beneficial for hemodynamically unstable brain-dead donors to increase the quantity and quality of organs available for transplantation Ref. Additional data may be necessary to further define the role of regular insulin in this setting.

Based on a consensus document sponsored by the American Society of Transplant Surgeons and the American Society of Transplantation, the use of regular insulin (in combination with vasopressin, methylprednisolone, and liothyronine) is effective and recommended for hormonal resuscitation in brain-dead donors Ref.

  Diabetic ketoacidosisLevel of Evidence [G]

Based on the American Diabetes Association consensus statement on hyperglycemic crises in adult patients with diabetes, insulin regular is effective and recommended for the treatment of patients with diabetic ketoacidosis Ref.

  Gestational diabetes mellitusLevel of Evidence [G]

Based on the American Diabetic Association (ADA) guidelines for the Standards of Medical Care in Diabetes, insulin is effective and recommended in the treatment of gestational diabetes mellitus (preferred therapy) Ref.

  Hyperglycemia during critical illnessLevel of Evidence [G]

Data from two prospective, randomized, controlled trials in the ICU population supports the use of insulin regular in the management of hyperglycemia in this patient population Ref. However, some data suggests that intensive glucose control is not associated with reduced mortality or morbidity in the general critically ill adult patient or may even increase mortality Ref. The 2011 ACP clinical practice guideline for the management of glycemic control in hospitalized patients recommends against the use of intensive insulin therapy in non-SICU/MICU patients which includes patients suffering a myocardial infarction. Therefore, the 2012 SCCM guidelines suggests a glycemic goal range of 100 to 150 mg/dL.

Based on the Society of Critical Care Medicine (SCCM) guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients, insulin regular is an effective and recommended treatment option in this patient population to reduce the risk of morbidity and mortality in specific ICU subpopulations (eg, perioperative, postoperative cardiac surgery, post-traumatic injury, and neurologic injury patients) and the general ICU patient, respectively.

  HyperkalemiaLevel of Evidence [G]

Based on the American Heart Association (AHA) guidelines for cardiopulmonary resuscitation and emergency cardiovascular care, insulin regular (in combination with glucose) is effective and recommended in the management of severe cardiotoxicity or cardiac arrest due to hyperkalemia Ref.

  Hyperosmolar hyperglycemic stateLevel of Evidence [G]

Based on the American Diabetes Association consensus statement on hyperglycemic crises in adult patients with diabetes, insulin regular is effective and recommended for the treatment of patients with hyperosmolar hyperglycemic state Ref.

Level of Evidence Definitions
  Level of Evidence Scale
Clinical Practice Guidelines

Acute Coronary Syndromes (ACS):

ACCF/AHA, “2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction,” December 2012.

Advanced Cardiac Life Support (ACLS)/Emergency Cardiovascular Care (ECC):

AHA, “2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” October 2015

AHA, “2010 Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” November 2010.

Coronary Artery Bypass Graft Surgery:

“2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery,” November 2011

Diabetes Mellitus:

American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE), “Consensus Statement on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary,” January 2018

American Diabetes Association, “Standards of Medical Care in Diabetes – 2018,” January 2018

Diabetes Canada, “Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,” 2018

Endocrine Society, “Diabetes Technology-Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline,” 2016

Glycemic Control, Hospitalized Patients:

American College of Physicians, “Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients,” February 2011

Society of Critical Care Medicine (SCCM), “Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients,” December 2012.

Sepsis:

“Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” March 2017

Usual Infusion Concentrations: Pediatric

IV infusion: 0.1 unit/mL, 0.5 unit/mL, or 1 unit/mL

Usual Infusion Concentrations: Adult

IV infusion: 100 units in 100 mL (concentration: 1 unit/mL) of NS

Administration: IV

Do not administer U-500 regular insulin or mixtures of insulin formulations IV. Do not use if solution is viscous or cloudy; use only if clear and colorless. U-100 regular insulin may be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required.

IV infusions: To minimize insulin adsorption to plastic IV tubing: Insulin loss will occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (Greenwood 2012; Hirsch 1977; Hirsch 1981; Rocchio 2013; Thompson 2012). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (SCCM [Jacobi 2012]; Thompson 2012).

Note: Also refer to institution-specific protocols where appropriate.

If insulin is required prior to the availability of the insulin drip, regular insulin should be administered by IV push injection.

Because of insulin adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (Moghissi 2009).

Administration: Injectable Detail

pH: 7 to 7.8

Administration: Subcutaneous

Do not use if solution is viscous or cloudy; use only if clear and colorless. Regular insulin should be administered approximately 30 minutes before a meal. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, buttocks, or abdomen; rotate injection sites within the same region to avoid lipodystrophy.

U-100 regular insulin: When mixing U-100 regular insulin with NPH insulin, U-100 regular insulin should be drawn into syringe first.

FlexPen: Prime the needle before each injection with 2 units of insulin. Once injected, hold the FlexPen device in the skin for a count of 6 after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.

U-500 regular insulin (concentrated): Do not dilute or mix U-500 regular insulin.

Vials: U-500 regular insulin vials are to be used only in conjunction with a dedicated U-500 insulin syringe; dosage conversion is not required with the U-500 syringe. Only in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be necessary. When using a U-100 syringe or a tuberculin syringe to deliver Humulin R U-500 (from vial), a conversion step is required to ensure the correct amount of Humulin R U-500 is drawn up in the syringe. To avoid dosing errors when using a U-100 insulin syringe, the prescribed dose should be written in actual insulin units and as unit markings on the U-100 insulin syringe (eg , Humulin R U-500 50 units = 10 units on a U-100 insulin syringe). To avoid dosing errors when using a tuberculin syringe, the prescribed dose should be written in actual insulin units and as a volume (eg, Humulin R U-500 50 units = 0.1 mL on a tuberculin syringe).

KwikPen: Do not perform dose conversions when using the KwikPen; the dose window shows the number of units to be injected. Do not transfer KwikPen insulin into a syringe for administration. Prime the needle before each injection with 5 units of insulin. Once the dose is injected, hold the device in the skin for a count of 5 after the dose dial has returned to 0 units before removing the needle to ensure the full dose has been administered.

CSII: Novolin regular insulin (U-100) is not recommended for use in external SubQ insulin infusion pump due to precipitation concerns (manufacturer labeling). U-500 regular insulin is generally not recommended for use in an insulin pump but may be used in select patients under the supervision of a qualified provider (AACE [Grunberger 2010]; Endocrine Society [Peters 2016]).

Administration: Pediatric

Parenteral: Do not use if solution is viscous or cloudy; use only if clear and colorless.

SubQ: Administer 30 to 60 minutes before meals. Cold injections should be avoided. Administration is usually made into the subcutaneous fat of the thighs, arms, buttocks, or abdomen, with sites rotated. When mixing regular insulin with other insulin preparations, regular insulin should be drawn into the syringe first. While not preferred, regular insulin may be infused SubQ by external insulin pump (eg, when rapid-acting insulin not available) (Danne [ISPAD], 2014); however, when used in an external pump, it is not recommended to be diluted with other solutions.

Concentrated preparation: U-500 formulation: Do not dilute or mix U-500 regular insulin. U-500 regular insulin vials are to be used only in conjunction with a dedicated U-500 insulin syringe; dosage conversion is not required with the U-500 syringe. Only in cases where the U-500 insulin syringe is not available, a U-100 insulin syringe or a tuberculin syringe may be necessary.When using a U-100 syringe or a tuberculin syringe to deliver Humulin R U-500 (from vial), a conversion step is required to ensure the correct amount of Humulin R U-500 is drawn up in the syringe. To avoid dosing errors when using a U-100 insulin syringe, the prescribed dose should be written in actual insulin units and as unit markings on the U-100 insulin syringe (eg, Humulin R U-500 50 units = 10 units on a U-100 insulin syringe). To avoid dosing errors when using a tuberculin syringe, the prescribed dose should be written in actual insulin units and as a volume (eg, Humulin R U-500 50 units = 0.1 mL on a tuberculin syringe). Do not perform dose conversions when using the KwikPen; the dose window shows the number of units to be injected. Do not transfer KwikPen insulin into a syringe for administration.

IM: May be administered IM in selected clinical situations; close monitoring of blood glucose and serum potassium as well as medical supervision is required.

IV: Regular U-100 insulin is the preferred insulin formulation approved for IV administration; requires close monitoring of blood glucose and serum potassium; appropriate medical supervision. If possible, do not administer mixtures of insulin formulations intravenously. IV administration of U-500 regular insulin is not recommended.

Continuous IV Infusion: Insulin loss will occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (Greenwood 2012; Hirsch 1977; Hirsch 1981; Rocchio 2013; Thompson 2012). To minimize insulin adsorption to plastic (eg, PVC, polyethylene polyolefin, polypropylene) IV tubing: Prior to administration, flush IV tubing with a priming volume of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (Goldberg 2006; Jacobi 2012; Thompson 2012). Studies examining this issue in neonates suggest that flushing the IV tubing prior to administration reduces adsorption and provides improved and more predictable insulin delivery; however, the combination of flushing along with preconditioning (waiting a predefined time after flushing the IV line before infusing) provides the greatest reduction in insulin adsorption; wait times for preconditioning varied among studies from 20 to 60 minutes; flush volumes varied and were as high as 20 mL (Fuloria 1998; Hewson 2000; Simeon 1994). Refer to institution-specific protocols where appropriate.

If insulin is required prior to the availability of the insulin drip, regular insulin should be administered by IV push injection.

Because of adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on the effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SubQ dosing regimen (Moghissi 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SubQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (Moghissi 2009)

Dietary Considerations

Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.

Storage/Stability

Humulin R U-100: Store unopened vials in refrigerator between 2°C and 8°C (36°F to 46°F) until expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), vials may be stored for up to 31 days in the refrigerator between 2°C and 8°C (36°F to 46°F) or at room temperature of ≤30°C (≤86°F).

Humulin R U-500:

Vials: Store unopened vials (not in use) in a refrigerator (2°C to 8°C [36°F to 46°F]) until expiration date or may be stored at room temperature <30°C [86°F]) for up to 40 days. Protect from heat and light; do not freeze and do not use if the vial has been frozen. Store vials currently opened (in use) in a refrigerator (2°C to 8°C [36°F to 46°F]) or at room temperature <30°C [86°F]) and discard after 40 days. Do not shake vial.

KwikPen: Store unopened pens (not in use) in a refrigerator (2°C to 8°C [36°F to 46°F]) until expiration date or may be stored at room temperature (<30°C [86°F]) for up to 28 days. Protect from heat and light; do not freeze or use if pen has been frozen. Store in-use (opened) pens at room temperature (<30°C [86°F]) and discard pen after 28 days; do not refrigerate. For single-patient use only.

Novolin R:

Vials: Store unopened vials in refrigerator between 2°C and 8°C (36°F to 46°F) until product expiration date or at room temperature ≤25°C (≤77°F) for up to 42 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), store vials at room temperature ≤25°C (≤77°F) for up to 42 days; refrigeration of in-use vials is not recommended.

FlexPen: Store unopened (not in use) pens in refrigerator between 2°C and 8°C (36°F to 46°F) until product expiration date or at room temperature (<30°C [86°F]) for up to 28 days; store in use (opened) pens at room temperature (<30°C [86°F]) for up to 28 days. Do not use if pen has been frozen; keep away from heat and light. For single-patient use only.

Canadian labeling (not in US labeling): All products: Unopened vials, cartridges, and pens should be stored under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials, cartridges, and pens should be stored at room temperature <25°C (<77°F) for up to 4 weeks. Once punctured (in use), Novolin ge vials, cartridges, and pens may be stored for up to 1 month at room temperature <25°C (<77°F) for vials or <30°C (<86°F) for pens/cartridges; do not refrigerate.

For SubQ administration: Humulin R U-100: According to the manufacturer, insulin diluted with the manufacturer’s sterile diluent in a glass vial may be stored at 30°C (86°F) for up to 14 days or at 5°C (41°F) for up to 28 days. Do not store diluted insulin in a plastic syringe. Store unused sterile diluent at room temperature; once in-use, the sterile diluent vial should be used within 28 days (data on file [Eli Lilly 2018]).

For IV infusion:

Humulin R U-100: Stable for 48 hours at room temperature or for 48 hours under refrigeration followed by 48 hours at room temperature.

Novolin R: Stable for 24 hours at room temperature

Note: After dilution of 100 units of regular human insulin (product not specified) in 100 mL of 0.9% NaCl (PVC bag), the solution is stable under refrigeration between 2°C and 8°C (36°F to 46°F) for up to 336 hours (Rocchio 2013).

Preparation for Administration: Adult

For SubQ administration: Humulin R U-100: May be diluted with manufacturer’s sterile diluent down to a concentration of 10 units/mL (U-10) (data on file [Eli Lilly 2018]).

For IV infusion:

Humulin R U-100: May be diluted in NS or D5W to concentrations of 0.1 to 1 unit/mL.

Novolin R: May be diluted in NS, D5W, or D10W with 40 mEq/L potassium chloride at concentrations of 0.05 to 1 unit/mL.

Preparation for Administration: Pediatric

Parenteral:

SubQ:

Humulin R U-100: May be diluted with the universal diluent, Sterile Diluent for Humalog, Humulin N, Humulin R, Humulin 70/30, and Humulin R U-500, to a concentration of 10 units/mL (U-10) or 50 units/mL (U-50).

Novolin R: Insulin Diluting Medium for NovoLog is not intended for use with Novolin R or any insulin product other than insulin aspart.

Regular Insulin may be mixed with other insulins; when mixing regular insulin with other insulin preparations, regular insulin should be drawn into syringe first.

IV infusion: Only use U-100 preparations.

Humulin R: May be diluted in NS or D5W to concentrations of 0.1 to 1 unit/mL.

Novolin R: May be diluted in NS, D5W, or D10W with 40 mEq/L potassium chloride at concentrations of 0.05 to 1 unit/mL.

Note: ISMP and Vermont Oxford Network recommend a standard concentration of 0.1 or 0.5 units/mL for neonates (ISMP 2011).

Compatibility

See Trissel’s IV Compatibility Database

Medication Patient Education with HCAHPS Considerations

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience weight gain. Have patient report immediately to prescriber signs of low blood sugar (dizziness, headache, fatigue, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating), signs of low potassium (muscle pain or weakness, muscle cramps, or an abnormal heartbeat), anxiety, severe injection site irritation, vision changes, chills, severe dizziness, passing out, mood changes, seizures, burning or numbness feeling, slurred speech, swelling of arms or legs, or change in skin to thick or thin at injection site (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.

Medication Safety Issues
  Sound-alike/look-alike issues:
  High alert medication:
  Geriatric Patients: High-Risk Medication:
  Administration issues:
  Other safety concerns:
Contraindications

Hypersensitivity to regular insulin or any component of the formulation; during episodes of hypoglycemia.

Documentation of allergenic cross-reactivity for insulin is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long-standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.

• Hypersensitivity: Severe, life-threatening, generalized allergic reactions, including anaphylaxis, may occur. If hypersensitivity reactions occur, discontinue therapy, treat the patient with supportive care and monitor until signs and symptoms resolve.

• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV insulin use and supplement potassium when necessary.

Disease-related concerns:

• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones (TZDs) may cause dose-related fluid retention and lead to or exacerbate heart failure, particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of heart failure. If heart failure develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.

• Hepatic impairment: Use with caution in patients with hepatic impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.

• Renal impairment: Use with caution in patients with renal impairment; increased risk of hypoglycemia. Dosage requirements may be reduced and patients may require more frequent dose adjustment and glucose monitoring.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Hospitalized patients with diabetes: Exclusive use of a sliding scale insulin regimen in the inpatient hospital setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, basal insulin or basalplus bolus is preferred. In noncritically ill patients with adequate nutritional intake, a combination of basal insulin, nutritional, and correction components is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia. A blood glucose value <70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2018).

Dosage form specific issues:

• Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).

• Product variation: Human insulin differs from animal-source insulin. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Verify product label prior to administration to prevent medication errors.

• U-500 regular insulin: U-500 regular insulin is a concentrated insulin formulation which contains 500 units of insulin per mL and is intended for subQ administration only; do not administer IV or IM. U-500 regular insulin is generally not recommended for use in an insulin pump, but may be used in select patients under the supervision of a qualified provider (AACE [Grunberger 2010]; Endocrine Society [Peters 2016]). Prescribe only to patients who require more than 200 units of insulin per day. Doses from a U-500 regular insulin vial should be drawn up only with a dedicated U-500 insulin syringe. Do not mix or dilute U-500 regular insulin with other insulin formulations. Insulin U-500 also has a delayed onset and longer duration of action compared to regular insulin U-100, and has both prandial and basal properties (ADA 2018). Do not perform dose conversions when using the KwikPen, the dose window shows the number of units to be injected. Do not transfer insulin from the KwikPen to a syringe for administration.

Other warnings/precautions:

• IV administration: Regular insulin U-100 (ie, 100 units/mL) may be administered IV in selected clinical situations (eg, DKA, hyperkalemia); close monitoring of blood glucose and serum potassium as well as medical supervision is required. Do not administer U-500 regular insulin IV.

• Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.

Geriatric Considerations

Intensive glucose control (HbA1c <6.5%) has been linked to increased all-cause and cardiovascular mortality, hypoglycemia requiring assistance, and weight gain in adult type 2 diabetes. How “tightly” to control a geriatric patient’s blood glucose needs to be individualized. Such a decision should be based on several factors, including the patient’s functional and cognitive status, how well he/she recognizes hypoglycemic or hyperglycemic symptoms, and how to respond to them and other disease states. An HbA1c <7.5% is an acceptable endpoint for a healthy older adult, while <8% is acceptable for frail elderly patients, those with a duration of illness >10 years, or those with comorbid conditions and requiring combination diabetes medications. In patients with advanced microvascular complications and/or a life expectancy <5 years, a target HbA1c of 8% to 9% is reasonable. Patients who are unable to accurately draw up their dose will need assistance, such as prefilled syringes. Initial doses may require considerations for renal function in the elderly with dosing adjusted subsequently based on blood glucose monitoring. For elderly patients with diabetes who are relatively healthy, attaining target goals for aspirin use, blood pressure, lipids, smoking cessation, and diet and exercise may be more important than normalized glycemic control.

Pregnancy Considerations

Animal reproduction studies have not been conducted. Exogenous insulin bound to anti-insulin antibodies can be detected in cord blood (Menon 1990).

In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 2005; ADA 2018; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2018; Blumer 2013; Lambert 2013).

Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28 to 32 weeks’ gestation. Following delivery, insulin requirements decrease rapidly (ACOG 2005).

Insulin therapy is the preferred treatment of type 1 and type 2 diabetes in pregnant women, as well as GDM when pharmacologic therapy is needed (ACOG 190 2018; ADA 2018). Rapid acting insulins may be preferred over regular human insulin in women trying to conceive (Blumer 2013); however, there is no need to switch a pregnant woman who is well-controlled on injectable human insulin to a short acting analogue (Lambert 2013). Regular insulin is used intravenously for glycemic control during labor.

Breast-Feeding Considerations

Both exogenous and endogenous insulin are present in breast milk (study not conducted with this preparation) (Whitmore 2012). Breastfeeding is encouraged for all women, including those with type 1, type 2, or GDM (ACOG 2005; ADA 2018; Blumer 2013; Metzger 2007). A small snack (such as milk) before breastfeeding may help decrease the risk of hypoglycemia in women with pregestational diabetes (ACOG 2005; Reader 2004).

Adverse events have not been reported in breastfeeding infants following use of regular insulin for injection. Regular insulin is compatible with breastfeeding; however, adjustments of the mothers’ insulin dose may be needed.

Lexicomp Pregnancy & Lactation, In-Depth
Briggs’ Drugs in Pregnancy & Lactation
Adverse Reactions

Frequency not always defined.

Cardiovascular: Peripheral edema

Dermatologic: Erythema at injection site, injection site pruritus

Endocrine & metabolic: Hypoglycemia, hypokalemia, weight gain

Hypersensitivity: Anaphylaxis, hypersensitivity, hypersensitivity reaction

Local: Hypertrophy at injection site, lipoatrophy at injection site

Allergy and Idiosyncratic Reactions
Toxicology
Metabolism/Transport Effects

None known.

Drug Interactions 

Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Exceptions: Danazol. Risk C: Monitor therapy

Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Beta-Blockers: May enhance the hypoglycemic effect of Insulins. Exceptions: Levobunolol; Metipranolol. Risk C: Monitor therapy

Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins. Risk C: Monitor therapy

Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea. Exceptions: Liraglutide. Risk D: Consider therapy modification

Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: If liraglutide is used for the treatment of diabetes (Victoza), consider insulin dose reductions. The combination of liraglutide and insulin should be avoided if liraglutide is used exclusively for weight loss (Saxenda). Risk D: Consider therapy modification

Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

Maitake: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Risk C: Monitor therapy

Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin. Monitor closely. Risk D: Consider therapy modification

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Risk C: Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Risk C: Monitor therapy

Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, dose reductions should be considered to reduce the risk of hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure. Risk D: Consider therapy modification

Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control. Risk D: Consider therapy modification

Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Risk C: Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. Risk X: Avoid combination

Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Risk C: Monitor therapy

Sodium-Glucose Cotransporter 2 (SLGT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Monitoring Parameters

Critically ill patients receiving insulin infusion: Blood glucose every 1 to 2 hours. Note: Every 4 hour blood glucose monitoring is not recommended unless a low hypoglycemia rate is demonstrated with the insulin protocol used. Arterial or venous whole blood sampling is recommended for patients in shock, on vasopressor therapy, or with severe edema, and when on a prolonged insulin infusion (SCCM [Jacobi 2012]).

Diabetes mellitus: Plasma glucose, electrolytes, HbA1c (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018]); renal function, hepatic function, weight

DKA/HHS: Serum electrolytes, glucose, BUN, creatinine, osmolality, venous pH (repeat arterial blood gases are generally unnecessary), anion gap, urine output, urinalysis, mental status

Hyperkalemia: Serum potassium and glucose must be closely monitored to avoid hypokalemia, rebound hyperkalemia, and hypoglycemia.

Reference Range

Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018):

HbA1c: <7% (a more aggressive [<6.5%] or less aggressive [<8%] HbA1c goal may be targeted based on patient-specific characteristics)

Preprandial capillary blood glucose: 80 to 130 mg/dL

Peak postprandial capillary blood glucose: <180 mg/dL

Recommendations for glycemic control in older adults (≥65 years) with diabetes (ADA 2018):

HbA1c: <7.5% (healthy); <8% (complex/intermediate health); <8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)

Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)

Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)

Recommendations for glycemic control in pediatric (all age groups) patients with type 1 diabetes (ADA 2018):

HbA1c: <7.5% (individualization may be appropriate based on patient-specific characteristics; <7% is reasonable if it can be achieved without excessive hypoglycemia)

Preprandial capillary blood glucose: 90 to 130 mg/dL

Bedtime and overnight capillary blood glucose: 90 to 150 mg/dL

Recommendations for hospitalized adult patients with diabetes (ADA 2018): Target glucose range: 140 to 180 mg/dL (majority of critically ill and noncritically ill patients; <140 mg/dL may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia). Initiate insulin therapy for persistent hyperglycemia at ≥180 mg/dL

Recommendations for perioperative care in adult patients with diabetes (ADA 2018): Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL

Advanced Practitioners Physical Assessment/Monitoring

Obtain HbA1c (at least twice annually if meeting goals and quarterly for patients not meeting treatment goals or with therapy change), serum glucose, electrolytes, renal function tests, and liver function tests. Obtain blood glucose every 1 to 2 hours in critically ill patients receiving an infusion. Obtain electrolytes, glucose, renal function tests, osmolality, venous pH, anion gap, urine output, urinalysis, and assess mental status in patient with DKA/HHS. Obtain serum potassium and glucose in patients with hyperkalemia. Monitor weight. Monitor for hypoglycemia at regular intervals during therapy. Teach patient proper use, including appropriate injection technique and syringe/needle disposal, and monitoring requirements. Refer to dietician and/or diabetes self-management education.

Nursing Physical Assessment/Monitoring

Check ordered labs and report abnormalities. Monitor for hypoglycemia at regular intervals during therapy. Teach patient proper use, including appropriate injection technique and syringe/needle disposal, and monitoring requirements. Educate and instruct patient to report signs of hypoglycemia (dizziness, headache, fatigue, weakness, shaking, fast heartbeat, confusion, hunger, or sweating) or hypokalemia (muscle pain or weakness, muscle cramps, or an abnormal heartbeat). May need referral to dietician and/or diabetes self-management education.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection:

HumuLIN R: 100 units/mL (3 mL, 10 mL) [contains metacresol]

NovoLIN R: 100 units/mL (10 mL) [contains metacresol]

NovoLIN R ReliOn: 100 units/mL (10 mL) [contains metacresol]

Solution, Subcutaneous:

HumuLIN R U-500 (CONCENTRATED): 500 units/mL (20 mL) [contains metacresol]

Solution Pen-injector, Subcutaneous:

HumuLIN R U-500 KwikPen: 500 units/mL (3 mL) [contains metacresol]

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Pen-injector, Subcutaneous:

Entuzity Kwikpen: 500 units/mL (3ml) [contains METACRESOL]

Anatomic Therapeutic Chemical (ATC) Classification
  • A10AB
Generic Available (US)

No

Pricing: US

Solution (HumuLIN R Injection)

100 units/mL (per mL): $17.84

Solution (HumuLIN R U-500 (CONCENTRATED) Subcutaneous)

500 units/mL (per mL): $89.22

Solution (NovoLIN R Injection)

100 units/mL (per mL): $16.52

Solution (NovoLIN R ReliOn Injection)

100 units/mL (per mL): $16.52

Solution Pen-injector (HumuLIN R U-500 KwikPen Subcutaneous)

500 units/mL (per mL): $114.84

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer’s AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.

Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.

Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either E. coli or Saccharomyces cerevisiae. Regular insulin has an identical structure to that of native human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin regular is a short-acting insulin analog.

Pharmacodynamics/Kinetics

Note: Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SubQ), site of injection (onset and duration are progressively slower with SubQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.

Onset of action: SubQ: 0.25 to 0.5 hours

Peak effect: SubQ: U-100: 2.5 to 5 hours; U-500: 4 to 8 hours

Duration:

IV: U-100: 2 to 6 hours

SubQ: U-100: 4 to 12 hours (may increase with dose); U-500: 13 to 24 hours

Distribution: IV, SubQ: Vd: 0.26 to 0.36 L/kg

Bioavailability: SubQ: 55% to 77%

Half-life elimination: IV: ~0.5 to 1 hour (dose-dependent); SubQ: 1.5 hours

Time to peak, plasma: SubQ: 0.8 to 2 hours

Excretion: Urine

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: In general, morning appointments are advisable in patients with diabetes since endogenous cortisol levels are typically higher at this time; because cortisol increases blood sugar levels, the risk of hypoglycemia is less. It is important to confirm that the patient has eaten normally prior to the appointment and has taken all scheduled medications. If a procedure is planned with the expectation that the patient will alter normal eating habits ahead of time (eg, conscious sedation), diabetes medication dose may need to be modified in consultation with the patient’s physician. Patients with well-controlled diabetes can usually be managed conventionally for most surgical procedures. Although patients with diabetes usually recognize signs and symptoms of hypoglycemia and self-intervene before changes in or loss of consciousness occurs, they may not. Staff should be trained to recognize the signs (eg, unusual behavior or profuse sweating in patients who have diabetes) and treat patients who have hypoglycemia; a glucometer should be used to test patient blood glucose levels. Every dental office should have a protocol for managing hypoglycemia in conscious and unconscious patients. Having snack foods or oral glucose tablets or gels available, especially in practices where a large number of surgical procedures are performed, is also prudent (American Diabetes Association 2017).

Effects on Bleeding

No information available to require special precautions

Index Terms

Regular Insulin

FDA Approval Date
October 28, 1982
References

Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38(5):869-872.[PubMed 2266671]

American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins, “Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March 2005. Pregestational Diabetes Mellitus,” Obstet Gynecol, 2005, 105(3):675-85.[PubMed 15738045]

American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131(2):e49-e64.[PubMed 29370047]

American Diabetes Association (ADA). Diabetes Care. 2018;41(suppl 1):S1-S159. Available at: http://care.diabetesjournals.org/content/41/Supplement_1. Accessed June 8, 2018.

American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, “Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes,” Diabetes Care, 2004, 27(2):596-601.[PubMed 14747245]

American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.[PubMed 26446832]

Aronoff GR, Bennett WM, Berns JS, et al, eds. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.

Bergen PM, Kruger DF, Taylor AD, et al. Translating U-500R randomized clinical trial evidence to the practice setting: a diabetes educator/expert prescriber team approach. Diabetes Educ. 2017;43(3):311-323. doi: 10.1177/0145721717701579.[PubMed 28427304]

Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-4249.[PubMed 24194617 ]

Brown G and Dodek P, “Intravenous Insulin Nomogram Improves Blood Glucose Control in the Critically Ill,” Crit Care Med, 2001, 29(9):1714-9.[PubMed 11546970]

Brown K Jr, Setji TL, Hale SL, et al. Assessing the impact of an order panel utilizing weight-based insulin and standardized monitoring of blood glucose for patients with hyperkalemia. Am J Med Qual. 2018 Mar 1:1062860618764610. doi: 10.1177/1062860618764610.[PubMed 29553285]

Brunkhorst FM, Engel C, Bloos F, et al, “Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis,” N Engl J Med, 2008, 358(2):125-39.[PubMed 18184958]

Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention website. http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html. Updated January 5, 2012. Accessed March 18, 2016.

Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, et al; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364-382. doi: 10.1542/peds.2012-3494.[PubMed 23359574]

Danne T, Bangstad HJ, Deeb L, Jarosz-Chobot P, Mungaie L, et al; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2014;15 (suppl 20):115-134. doi: 10.1111/pedi.12184.[PubMed 25182312]

Fayfman M, Pasquel FJ, Umpierrez GE. Management of hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. Med Clin North Am. 2017;101(3):587-606. doi: 10.1016/j.mcna.2016.12.011.[PubMed 28372715]

Field JM, Hazinski MF, Sayre MR, et al, “Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122 (18 Suppl 3):640-56.[PubMed 20956217]

Fuhrman B, Zimmerman J, eds. Pediatric Critical Care. 4th ed. Elsevier Health; 2011.

Greenwood BC, Chesnick MA, Szumita PM, Belisle C, Cotugno M. Stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. Hosp Pharm. 2012;47(5):367-370.

Grunberger G, Bailey TS, Cohen AJ, et al; AACE Insulin Pump Management Task Force. Statement by the American Association of Clinical Endocrinologists Consensus Panel on insulin pump management. Endocr Pract. 2010;16(5):746-762. doi: 10.4158/EP.16.5.746.[PubMed 21356638]

Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(suppl 1):1-87. doi: 10.4158/EP15672.GL.[PubMed 25869408]

Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, “Preparing for Pediatric Emergencies: Drugs to Consider,” Pediatrics, 2008, 121(2):433-43.[PubMed 18245435]

Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 124(23):2610-42.[PubMed 22064600]

Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. Am J Hosp Pharm. 1977;34(6):583-588.[PubMed 406784]

Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. Am J Hosp Pharm. 1981;38(7):995-997.[PubMed 7020415]

Hood RC, Arakaki RF, Wysham C, Li YG, Settles JA, Jackson JA. Two treatment approaches for human regular U-500 insulin in patients with type 2 diabetes not achieving adequate glycemic control on high-dose U-100 insulin therapy with or without oral agents: a randomized, titration-to- target clinical trial [published correction appears in Endocr Pract. 2016;22(7):905]. Endocr Pract. 2015;21(7):782-793. doi: 10.4158/EP15612.OR.[PubMed 25813411]

Hopkins DF, Cotton SJ, and Williams G, “Effective Treatment of Insulin-Induced Edema Using Ephedrine,” Diabetes Care, 1993, 16(7):1026-8.[PubMed 8359096]

Humulin R (insulin regular) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; May 2018.

Humulin R, Humulin N, and Humulin 30/70 (insulin isophane, human biosynthetic [rDNA origin]) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; May 2016.

Humulin R U-500 (insulin regular concentrate) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; November 2018.

Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf

International Diabetes Federation, International Society for Pediatric and Adolescent Diabetes. Global IDF/ISPAD guideline for diabetes in childhood and adolescence. 2011. http://www.idf.org/e-library/guidelines/80-the-global-idf-ispad-guidelines-for-diabetes-in-childhood-and-adolescence.html. Accessed: October 21, 2013.

Jacobi J, Bircher N, Krinsley J, et al, “Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients,” Crit Care Med, 2012, 40(12):3251-76.[PubMed 23164767]

Joint Commission on Accreditation of Healthcare Organizations, “2005 National Patient Safety Goals.” Available at http://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm

Kirkman M, Briscoe VJ, Clark N, et al, “Diabetes in Older Adults: A Consensus Report,” J Am Geriatr Soc, 2012; doi: 10.1111/jgs.12035.[PubMed 23106132]

Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343. doi: 10.2337/dc09-9032.[PubMed 19564476]

Kitabchi AE, Umpierrez GE, Murphy MB, et al, “Hyperglycemic Crises in Diabetes,” Diabetes Care, 2004, 27(Suppl 1): 94-102.[PubMed 14693938]

Lambert K, Holt RI. The use of insulin analogues in pregnancy. Diabetes Obes Metab. 2013;15(10):888-900.[PubMed 23489521 ]

Lazar HL, Philippides G, Fitzgerald C, et al, “Glucose-Insulin-Potassium Solutions Enhance Recovery After Urgent Coronary Artery Bypass Grafting,” J Thorac Cardiovasc Surg, 1997, 113(2):354-60.[PubMed 9040630]

Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: an effective, less-expensive option. JAMA. 2017;318(1):23-24. doi:10.1001/jama.2017.6939.[PubMed 28604935]

Malhotra A, “Intensive Insulin in Intensive Care,” N Engl J Med, 2006, 354(5):516-8.[PubMed 16452564]

Malmberg K, “Prospective Randomised Study of Intensive Insulin Treatment on Long Term Survival After Acute Myocardial Infarction in Patients With Diabetes Mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group,” BMJ, 1997, 314(7093):1512-5.[PubMed 9169397]

Menon RK, Cohen RM, Sperling MA, et al, “Transplacental Passage of Insulin in Pregnant Women With Insulin-Dependent Diabetes Mellitus. Its Role in Fetal Macrosomia,” N Engl J Med, 1990, 323(5):309-15.[PubMed 2195347]

Metzger BE, Buchanan TA, Coustan DR, et al, “Summary and Recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus,” Diabetes Care, 2007, 30(Suppl 2):251-60.[PubMed 17596481]

Moghissi ES, Korytkowski MT, DiNardo M, et al, “American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,” Endocr Pract, 2009, 15(4):353-69.[PubMed 19454396]

Morley JE and Perry HM 3d, “The Management of Diabetes Mellitus in Older Individuals,” Drugs, 1991, 41(4):548-65.[PubMed 1711959]

Mueller-Schoop J, “Accidental Intravenous Self-Injection With Insulin Pen,” Lancet, 1993, 341(8849):894.

Nathan DM, “Insulin Treatment in the Elderly Diabetic Patient,” Clin Geriatr Med, 1990, 6(4):923-31.[PubMed 2224755]

Newton L, Garvey WT, eds. Nutritional and medical management of diabetes mellitus in hospitalized patients. In: Mueller C, ed. In: Mueller CM, ed. A.S.P.E.N. Adult Nutrition Support Core Curriculum. 2nd edition. Silver Spring, MD: American Society for Parenteral and Enteral Nutrition; 2012:599. http://www.nutritioncare.org/

NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al, “Intensive Versus Conventional Glucose Control in Critically Ill Patients,” N Engl J Med, 2009, 360(13):1283-97.[PubMed 19318384 ]

Novolin ge (insulin regular) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; March 2016.

Novolin R (insulin regular) [prescribing information]. Princeton, NJ: Novo Nordisk; June 2018.

Oiknine R, Bernbaum M, and Mooradian AD, “A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus,” Drugs, 2005, 65(3):325-40.[PubMed 15669878]

Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922-3937. doi: 10.1210/jc.2016-2534.[PubMed 27588440]

Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” Am J Health Syst Pharm, 2011, 68(22):2176-82.[PubMed 22058104]

“Proceedings of the American College of Endocrinology Task Force on Inpatient Diabetes and Metabolic Control Consensus Conference, Washington, DC, USA, December 2003,” Endocr Pract, 2004, (10 Suppl 2):3-108.

Qaseem A, Humphrey LL, Chou R, et al, “Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians,” Ann Intern Med, 2011, 154(4):260-7.[PubMed 21320941]

Qaseem A, Humphrey LL, Sweet DE, et al. Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218-231.[PubMed 22312141]

Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. Curr Diab Rep. 2004;4(5):370-376.[PubMed 15461903 ]

Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-377.[PubMed 28101605]

Riddle MC, Rosenstock J, Gerich J, et al, “The Treat-to-Target Trial: Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients,” Diabetes Care, 2003, 26(11):3080-6.[PubMed 14578243]

Rocchio MA, Belisle CD, Greenwood BC, Cotugno MC, Szumita PM. Evaluation of the maximum beyond-use-date stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. Diabetes Metab Syndr Obes. 2013;6:389-392.[PubMed 24143117]

Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive Pharmacologic Donor Management Results in More Transplanted Organs. Transplantation. 2003a;75(4):482-487.[PubMed 12605114]

Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003b;75(8):1336-1341.[PubMed 12717226]

Rosengard BR, Feng S, Alfrey EJ, et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant. 2002;2(8):701-711.[PubMed 12243491]

Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the number of organs available for transplantation.Clin Transplant, 2007;21(3):405-409.[PubMed 17488392 ]

Silverstein J, Klingensmith G, Copeland K, et al, “Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,” Diabetes Care, 2005, 28(1):186-212.[PubMed 15616254]

Simeon PS, Geffner ME, Levin SR, et al, “Continuous Insulin Infusions in Neonates: Pharmacologic Availability of Insulin in Intravenous Solutions,” J Pediatr, 1994, 124(5 Pt 1):818-20.[PubMed 8176576]

Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. Diabetes Technol Ther.2012;14(10):912-916.[PubMed 22746979]

van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354(5):449-461.[PubMed 16452557]

van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345(19):1359-1367.[PubMed 11794168]

Vanden Hoek TL, Morrison LJ, Shuster M, et al, “Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):829-61.[PubMed 20956228]

Wheeler DT, Schafers SJ, Horwedel TA, Deal EN, Tobin GS. Weight-based insulin dosing for acute hyperkalemia results in less hypoglycemia. J Hosp Med. 2016;11(5):355-357. doi: 10.1002/jhm.2545.[PubMed 26762588]

Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. Int J Endocrinol. 2012;2012:296368.[PubMed 22500167 ]

Wiener RS, Wiener DC, and Larson RJ, “Benefits and Risks of Tight Glucose Control in Critically Ill Adults: A Meta-Analysis,” JAMA, 2008, 300(8):933-44.[PubMed 18728267]

Wolfsdorf J, Craig ME, Daneman D, et al, “Diabetic Ketoacidosis,” Pediatr Diabetes, 2007, 8(1):28-43. Available at http://onlinelibrary.wiley.com/doi/10.1111/j.1399-5448.2007.00224.x/full[PubMed 17341289]

Wolfsdorf J, Glaser N, Sperling MA; American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care. 2006;29(5):1150-1159. doi: 10.2337/diacare.2951150.[PubMed 16644656]

Wolfsdorf JI, Allgrove J, Craig ME, Edge J, Glaser N, et al; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes. 2014;15 (suppl 20):154-179. doi: 10.1111/pedi.12165.[PubMed 25041509]

Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus Conference Report: Maximizing Use of Organs Recovered from the Cadaver Donor: Cardiac Recommendations: March 28-29, 2001, Crystal City, Va.Circulation. 2002;106(7):836-841.[PubMed 12176957]

Zeitler P, Haqq A, Rosenbloom A, Glaser N; Drugs and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Hyperglycemic hyperosmolar syndrome in children: pathophysiological considerations and suggested guidelines for treatment. J Pediatr. 2011;158(1):9-14. doi: 10.1016/j.jpeds.2010.09.048.[PubMed 21035820]

Zeitler P, Fu J, Tandon N, Nadeau K, Urakami T, Barrett T, Maahs D; International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2014. Type 2 diabetes in the child and adolescent. Pediatr Diabetes. 2014;15 (suppl 20):26-46. doi: 10.1111/pedi.12179.[PubMed 25182306]

Brand Names: International

Actrapid (DK, SG); Endulin Select (ZW); Glinux-R (MX); Huminsulin Basal (CH); Huminsulin Normal (AT); Humulin (UA); Humulin R (AE, AU, BB, BG, BH, BM, BZ, CL, CN, CO, CR, CY, CZ, DO, EE, EG, GT, GY, HK, HR, HU, ID, IL, IT, JO, KR, KW, LB, LI, LK, LT, LU, MX, MY, NI, NZ, PA, PE, PH, PK, PY, RO, SA, SE, SI, SK, SR, SV, TH, TR, VN); Humulin Regular (DK, FI, GR, PT, RU); Humulin S (GB); Humulina Regular (ES); Humuline R (BE); Iletin-R (IN); Insugen R (MY, TH); Insugen-R (ZW); Insuget R (PH); Insulet R (BD); Insulin Insulatard HM (CH); Insulina Humulin R (AR); Insuman (NO); Insuman Basal (ET, IE, TZ); Insuman R (CL); Insuman Rapid (TH, ZW); Jusline R (TZ); Scilin R (PH); Umuline Rapide (FR); Winsulin-R (TH); Wosulin R (BR, TZ)

Insulin Regular (Patient Education – Adult Medication)
You must carefully read the “Consumer Information Use and Disclaimer” below in order to understand and correctly use this information
Pronunciation

(IN soo lin REG yoo ler)

Brand Names: US

HumuLIN R U-500 (CONCENTRATED); HumuLIN R U-500 KwikPen; HumuLIN R [OTC]; NovoLIN R ReliOn [OTC]; NovoLIN R [OTC]

Brand Names: Canada

Entuzity KwikPen; Humulin R; Novolin ge Toronto

What is this drug used for?
  • It is used to lower blood sugar in patients with high blood sugar (diabetes).
What do I need to tell my doctor BEFORE I take this drug?
  • If you have an allergy to insulin or any other part of this drug.
  • If you are allergic to any drugs like this one, any other drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
  • If you have low blood sugar.
  • This is not a list of all drugs or health problems that interact with this drug.
  • Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.
What are some things I need to know or do while I take this drug?
  • All products:
  • Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists.
  • Allergic reactions have happened with this drug. Rarely, some reactions can be very bad or life-threatening. Talk with the doctor.
  • Be sure you have the right insulin product. Insulin products come in many containers like vials, cartridges, and pens. Be sure that you know how to measure and get your dose ready. If you have any questions, call your doctor or pharmacist.
  • Low blood sugar may happen with this drug. Very low blood sugar can lead to seizures, passing out, long lasting brain damage, and sometimes death. Talk with the doctor.
  • Low blood potassium may happen with this drug. If not treated, this can lead to a heartbeat that is not normal, very bad breathing problems, and sometimes death. Talk with the doctor.
  • Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.
  • Some diabetes drugs like pioglitazone or rosiglitazone may cause heart failure or make it worse in people who already have it. Using insulin with these drugs may increase this risk. If you also take one of these drugs, talk with the doctor.
  • Do not switch between different forms of this drug without first talking with the doctor.
  • It may be harder to control your blood sugar during times of stress like when you have a fever, an infection, an injury, or surgery. A change in level of physical activity or exercise and a change in diet may also affect your blood sugar. Talk with your doctor.
  • Wear disease medical alert ID (identification).
  • Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.
  • Check your blood sugar as you have been told by your doctor.
  • Have blood work checked as you have been told by the doctor. Talk with the doctor.
  • Avoid drinking alcohol or taking products that have alcohol in them while taking this drug.
  • Do not share your insulin product with another person. This includes any pens, cartridge devices, needles, or syringes, even if the needle has been changed. Sharing may pass infections from one person to another. This includes infections you may not know you have.
  • If you are 65 or older, use this drug with care. You could have more side effects.
  • Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.
  • Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.
  • U-500 shot product:
  • This brand of insulin is 5 times stronger than other brands. Use extra care when you measure a dose. Accidental overdose may lead to very bad side effects or life-threatening low blood sugar. Talk with the doctor.
What are some side effects that I need to call my doctor about right away?
  • WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
  • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
  • Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.
  • Anxiety.
  • Change in eyesight.
  • Chills.
  • Very bad dizziness or passing out.
  • Mood changes.
  • Seizures.
  • Slurred speech.
  • Very bad irritation where the shot was given.
  • A burning, numbness, or tingling feeling that is not normal.
  • Swelling in the arms or legs.
  • Change in skin to thick or thin where the shot was given.
  • Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Call the doctor right away if any of these signs occur. Follow what you have been told to do if low blood sugar occurs. This may include taking glucose tablets, liquid glucose, or some fruit juices.
What are some other side effects of this drug?
  • All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
  • Weight gain.
  • Irritation where the shot is given.
  • These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.
  • You may report side effects to your national health agency.
How is this drug best taken?
  • Use this drug as ordered by your doctor. Read all information given to you. Follow all instructions closely.
  • All products:
  • It is given as a shot into the fatty part of the skin in the upper arm, thigh, buttocks, or stomach area.
  • If you will be giving yourself the shot, your doctor or nurse will teach you how to give the shot.
  • Follow how to use as you have been told by the doctor or read the package insert.
  • Wash your hands before use.
  • Take 30 minutes before meals.
  • Move the site where you give the shot with each shot.
  • Do not shake.
  • Do not give into red or irritated skin.
  • Do not use if the solution is cloudy, leaking, or has particles.
  • Do not use if solution changes color.
  • Throw away needles in a needle/sharp disposal box. Do not reuse needles or other items. When the box is full, follow all local rules for getting rid of it. Talk with a doctor or pharmacist if you have any questions.
  • Do not use outdated insulin.
  • Keep using this drug as you have been told by your doctor or other health care provider, even if you feel well.
  • Follow the diet and workout plan that your doctor told you about.
  • Be sure you know what to do if you do not eat as much as normal or if you skip a meal.
  • U-100 vials:
  • Do not draw into a syringe and store for future use.
  • It may be given into a vein by a doctor or other healthcare provider.
  • Some brands of this drug must not be used in an insulin pump unless your doctor tells you to. If you will be using an insulin pump, check with your doctor or pharmacist to see if your brand may be used in a pump.
  • If you are using this drug in a pump, be sure you know how to use it. Follow what your doctor has told you or read the package insert. Change the drug and parts of the pump when you have been told.
  • U-100 cartridges and pens:
  • Remove all pen needle covers before injecting a dose (there may be 2). If you are not sure what type of pen needle you have or how to use it, talk with the doctor.
  • Do not move this drug from the pen to a syringe or mix with other types of insulin.
  • This product may make a clicking sound as you prepare the dose. Do not prepare the dose by counting the clicks. Doing so could lead to using the wrong dose.
  • U-500 vials:
  • If you are using the U-500 vials, you will need to use a special insulin syringe. Only use the special insulin syringe to measure and inject your dose. If you use the wrong syringe, you may take the wrong dose of insulin U-500. The wrong dose can lead to low or high blood sugar. Talk with your doctor.
  • Do not mix this insulin in the same syringe with other types of insulin.
  • Do not draw into a syringe and store for future use.
  • Do not mix with other liquids.
  • U-500 prefilled pens:
  • Remove all pen needle covers before injecting a dose (there may be 2). If you are not sure what type of pen needle you have or how to use it, talk with the doctor.
  • Do not move this drug from the pen to a syringe or mix with other types of insulin.
  • This product may make a clicking sound as you prepare the dose. Do not prepare the dose by counting the clicks. Doing so could lead to using the wrong dose.
What do I do if I miss a dose?
  • Be sure you know what to do if you forget to take a dose.
  • If you are not sure what to do if you miss a dose, call your doctor.
How do I store and/or throw out this drug?
  • All products:
  • Store unopened containers in a refrigerator. Do not freeze.
  • Do not use if it has been frozen.
  • If an unopened container has been stored at room temperature, be sure you know how long you can leave this drug at room temperature before you need to throw it away. If you are not sure, talk with the doctor or pharmacist.
  • Protect from heat and light.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Throw away unused or expired drugs. Do not flush down a toilet or pour down a drain unless you are told to do so. Check with your pharmacist if you have questions about the best way to throw out drugs. There may be drug take-back programs in your area.
  • U-100 vials:
  • After opening, be sure you know how long the product is good for and how to store it. Ask the doctor or pharmacist if you are not sure.
  • U-100 cartridges and pens:
  • After opening, store at room temperature. Throw away any part not used after 28 days.
  • Do not put this drug back in the refrigerator after it has been used.
  • Take off the needle after each shot. Do not store this device with the needle on it.
  • U-500 vials:
  • You may store opened vials at room temperature or in a refrigerator. Throw away any part not used after 40 days.
  • U-500 prefilled pens:
  • After opening, store at room temperature. Throw away any part not used after 28 days.
  • Do not put this drug back in the refrigerator after it has been used.
  • Take off the needle after each shot. Do not store this device with the needle on it.
General drug facts
  • If your symptoms or health problems do not get better or if they become worse, call your doctor.
  • Do not share your drugs with others and do not take anyone else’s drugs.
  • Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.
  • Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.
  • Some drugs may have another patient information leaflet. If you have any questions about this drug, please talk with your doctor, nurse, pharmacist, or other health care provider.
  • If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.
Insulin Regular (Patient Education – Pediatric Medication)
You must carefully read the “Consumer Information Use and Disclaimer” below in order to understand and correctly use this information
Pronunciation

(IN soo lin REG yoo ler)

Brand Names: US

HumuLIN R U-500 (CONCENTRATED); HumuLIN R U-500 KwikPen; HumuLIN R [OTC]; NovoLIN R ReliOn [OTC]; NovoLIN R [OTC]

Brand Names: Canada

Entuzity KwikPen; Humulin R; Novolin ge Toronto

What is this drug used for?
  • It is used to lower blood sugar in patients with high blood sugar (diabetes).
What do I need to tell the doctor BEFORE my child takes this drug?
  • If your child has an allergy to this drug or any part of this drug.
  • If your child is allergic to any drugs like this one or any other drugs, foods, or other substances. Tell the doctor about the allergy and what signs your child had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.
  • If your child has low blood sugar.
  • This is not a list of all drugs or health problems that interact with this drug.
  • Tell the doctor and pharmacist about all of your child’s drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for your child to take this drug with all of his/her drugs and health problems. Do not start, stop, or change the dose of any drug your child takes without checking with the doctor.
What are some things I need to know or do while my child takes this drug?
  • All products:
  • Tell all of your child’s health care providers that your child is taking this drug. This includes your child’s doctors, nurses, pharmacists, and dentists.
  • Allergic reactions have happened with this drug. Rarely, some reactions can be very bad or life-threatening. Talk with the doctor.
  • Be sure you have the right insulin product. Insulin products come in many containers like vials, cartridges, and pens. Be sure that you know how to measure and get your dose ready. If you have any questions, call your doctor or pharmacist.
  • Low blood sugar may happen with this drug. Very low blood sugar can lead to seizures, passing out, long lasting brain damage, and sometimes death. Talk with the doctor.
  • Low blood potassium may happen with this drug. If not treated, this can lead to a heartbeat that is not normal, very bad breathing problems, and sometimes death. Talk with the doctor.
  • Have your child avoid tasks or actions that call for alertness until you see how this drug affects your child. These are things like riding a bike, playing sports, or using items such as scissors, lawnmowers, electric scooters, toy cars, or motorized vehicles.
  • Some diabetes drugs like pioglitazone or rosiglitazone may cause heart failure or make it worse in people who already have it. Using insulin with these drugs may increase this risk. If you also take one of these drugs, talk with the doctor.
  • Do not switch between different forms of this drug without first talking with the doctor.
  • It may be harder to control your child’s blood sugar during times of stress like when your child has a fever, an infection, an injury, or surgery. A change in level of physical activity or exercise and a change in diet may also affect your child’s blood sugar. Talk with the doctor.
  • Have your child wear disease medical alert ID (identification).
  • Have your child’s blood sugar checked as you have been told by your child’s doctor.
  • Have your child’s blood work checked often. Talk with your child’s doctor.
  • Alcohol interacts with this drug. Be sure your child does not drink alcohol or take products that have alcohol in them.
  • Do not share your child’s insulin product with another person. This includes any pens, cartridge devices, needles, or syringes, even if the needle has been changed. Sharing may pass infections from one person to another. This includes infections you may not know your child has.
  • If your child is pregnant or breast-feeding a baby:
  • Talk with the doctor if your child is pregnant, becomes pregnant, or is breast-feeding a baby. You will need to talk about the benefits and risks to your child and the baby.
  • U-500 shot product:
  • This brand of insulin is 5 times stronger than other brands. Use extra care when you measure a dose. Accidental overdose may lead to very bad side effects or life-threatening low blood sugar. Talk with the doctor.
What are some side effects that I need to call my child’s doctor about right away?
  • WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your child’s doctor or get medical help right away if your child has any of the following signs or symptoms that may be related to a very bad side effect:
  • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
  • Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.
  • Anxiety.
  • Change in eyesight.
  • Chills.
  • Very bad dizziness or passing out.
  • Mood changes.
  • Seizures.
  • Slurred speech.
  • Very bad irritation where the shot was given.
  • A burning, numbness, or tingling feeling that is not normal.
  • Swelling in the arms or legs.
  • Change in skin to thick or thin where the shot was given.
  • Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Call the doctor right away if any of these signs occur. Follow what you have been told to do if low blood sugar occurs. This may include taking glucose tablets, liquid glucose, or some fruit juices.
What are some other side effects of this drug?
  • All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your child’s doctor or get medical help if any of these side effects or any other side effects bother your child or do not go away:
  • Weight gain.
  • Irritation where the shot is given.
  • These are not all of the side effects that may occur. If you have questions about side effects, call your child’s doctor. Call your child’s doctor for medical advice about side effects.
  • You may report side effects to your national health agency.
How is this drug best given?
  • Give this drug as ordered by your child’s doctor. Read all information given to you. Follow all instructions closely.
  • All products:
  • It is given as a shot into the fatty part of the skin in the upper arm, thigh, buttocks, or stomach area.
  • If you will be giving your child the shot, your child’s doctor or nurse will teach you how to give the shot.
  • Follow how to give this drug as you have been told by your child’s doctor or read the package insert.
  • Wash your hands before use.
  • Give 30 minutes before meals.
  • Move the site where you give the shot with each shot.
  • Do not shake.
  • Do not give into red or irritated skin.
  • Do not use if the solution is cloudy, leaking, or has particles.
  • Do not use if solution changes color.
  • Throw away needles in a needle/sharp disposal box. Do not reuse needles or other items. When the box is full, follow all local rules for getting rid of it. Talk with a doctor or pharmacist if you have any questions.
  • Do not give outdated insulin.
  • Keep giving this drug to your child as you have been told by your child’s doctor or other health care provider, even if your child feels well.
  • Have your child follow the diet and workout plan your child’s doctor told you about.
  • Be sure you know what to do if your child does not eat as much as normal or if your child skips a meal.
  • U-100 vials:
  • Do not draw into a syringe and store for future use.
  • It may be given into a vein by a doctor or other healthcare provider.
  • Some brands of this drug must not be used in an insulin pump unless the doctor tells you to. If your child will be using an insulin pump, check with the doctor or pharmacist to see if your child’s brand may be used in a pump.
  • If you are using this drug in a pump, be sure you know how to use it. Follow what your doctor has told you or read the package insert. Change the drug and parts of the pump when you have been told.
  • U-100 cartridges and pens:
  • Remove all pen needle covers before injecting a dose (there may be 2). If you are not sure what type of pen needle you have or how to use it, talk with the doctor.
  • Do not move this drug from the pen to a syringe or mix with other types of insulin.
  • This product may make a clicking sound as you prepare the dose. Do not prepare the dose by counting the clicks. Doing so could lead to using the wrong dose.
  • U-500 vials:
  • If you are using the U-500 vials for your child’s doses, you will need to use a special insulin syringe. Only use the special insulin syringe to measure and inject your child’s dose. If you use the wrong syringe, you may give your child the wrong dose of insulin U-500. The wrong dose can lead to low or high blood sugar. Talk with your child’s doctor.
  • Do not mix this insulin in the same syringe with other types of insulin.
  • Do not draw into a syringe and store for future use.
  • Do not mix with other liquids.
  • U-500 prefilled pens:
  • Remove all pen needle covers before injecting a dose (there may be 2). If you are not sure what type of pen needle you have or how to use it, talk with the doctor.
  • Do not move this drug from the pen to a syringe or mix with other types of insulin.
  • This product may make a clicking sound as you prepare the dose. Do not prepare the dose by counting the clicks. Doing so could lead to using the wrong dose.
What do I do if my child misses a dose?
  • Be sure you know what to do if you forget to give your child a dose.
  • If you are not sure what to do if you miss giving your child a dose, call the doctor.
How do I store and/or throw out this drug?
  • All products:
  • Store unopened containers in a refrigerator. Do not freeze.
  • Do not use if it has been frozen.
  • If an unopened container has been stored at room temperature, be sure you know how long you can leave this drug at room temperature before you need to throw it away. If you are not sure, talk with the doctor or pharmacist.
  • Protect from heat and light.
  • Keep all drugs in a safe place. Keep all drugs out of the reach of children and pets.
  • Throw away unused or expired drugs. Do not flush down a toilet or pour down a drain unless you are told to do so. Check with your pharmacist if you have questions about the best way to throw out drugs. There may be drug take-back programs in your area.
  • U-100 vials:
  • After opening, be sure you know how long the product is good for and how to store it. Ask the doctor or pharmacist if you are not sure.
  • U-100 cartridges and pens:
  • After opening, store at room temperature. Throw away any part not used after 28 days.
  • Do not put this drug back in the refrigerator after it has been used.
  • Take off the needle after each shot. Do not store this device with the needle on it.
  • U-500 vials:
  • You may store opened vials at room temperature or in a refrigerator. Throw away any part not used after 40 days.
  • U-500 prefilled pens:
  • After opening, store at room temperature. Throw away any part not used after 28 days.
  • Do not put this drug back in the refrigerator after it has been used.
  • Take off the needle after each shot. Do not store this device with the needle on it.
General drug facts
  • If your child’s symptoms or health problems do not get better or if they become worse, call your child’s doctor.
  • Do not share your child’s drug with others and do not give anyone else’s drug to your child.
  • Keep a list of all your child’s drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your child’s doctor.
  • Talk with your child’s doctor before giving your child any new drug, including prescription or OTC, natural products, or vitamins.
  • Some drugs may have another patient information leaflet. If you have any questions about this drug, please talk with your child’s doctor, nurse, pharmacist, or other health care provider.
  • If you think there has been an overdose, call your poison control center or get medical care right away. Be ready to tell or show what was taken, how much, and when it happened.